Literature DB >> 22249255

Long-range epigenetic silencing of chromosome 5q31 protocadherins is involved in early and late stages of colorectal tumorigenesis through modulation of oncogenic pathways.

A R Dallosso1, B Øster, A Greenhough, K Thorsen, T J Curry, C Owen, A L Hancock, M Szemes, C Paraskeva, M Frank, C L Andersen, K Malik.   

Abstract

Loss of tumour suppressor gene function can occur as a result of epigenetic silencing of large chromosomal regions, referred to as long-range epigenetic silencing (LRES), and genome-wide analyses have revealed that LRES is present in many cancer types. Here we utilize Illumina Beadchip methylation array analysis to identify LRES across 800 kb of chromosome 5q31 in colorectal adenomas and carcinomas (n=34) relative to normal colonic epithelial DNA (n=6). This region encompasses 53 individual protocadherin (PCDH) genes divided among three gene clusters. Hypermethylation within these gene clusters is asynchronous; while most PCDH hypermethylation occurs early, and is apparent in adenomas, PCDHGC3 promoter methylation occurs later in the adenoma-carcinoma transition. PCDHGC3 was hypermethylated in 17/28 carcinomas (60.7%) according to methylation array analysis. Quantitative real-time reverse transcription-polymerase chain reaction showed that PCDHGC3 is the highest expressed PCDH in normal colonic epithelium, and that there was a strong reciprocal relationship between PCDHGC3 methylation and expression in carcinomas (R=-0.84). PCDH LRES patterns are reflected in colorectal tumour cell lines; adenoma cell lines are not methylated at PCDHGC3 and show abundant expression at the mRNA and protein level, while the expression is suppressed in hypermethylated carcinoma cell lines (R=-0.73). Short-interfering RNA-mediated reduction of PCDHGC3 led to a decrease of apoptosis in RG/C2 adenoma cells, and overexpression of PCDHGC3 in HCT116 cells resulted in the reduction of colony formation, consistent with tumour suppressor capabilities for PCDHGC3. Further functional analysis showed that PCDHGC3 can suppress Wnt and mammalian target of rapamycin signalling in colorectal cancer cell lines. Taken together, our data suggest that the PCDH LRES is an important tumour suppressor locus in colorectal cancer, and that PCDHGC3 may be a strong marker and driver for the adenoma-carcinoma transition.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22249255      PMCID: PMC3647107          DOI: 10.1038/onc.2011.609

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  57 in total

1.  Specific cytogenetic abnormalities in two new human colorectal adenoma-derived epithelial cell lines.

Authors:  C Paraskeva; S Finerty; R A Mountford; S C Powell
Journal:  Cancer Res       Date:  1989-03-01       Impact factor: 12.701

2.  Differential growth inhibition by the aspirin metabolite salicylate in human colorectal tumor cell lines: enhanced apoptosis in carcinoma and in vitro-transformed adenoma relative to adenoma relative to adenoma cell lines.

Authors:  D J Elder; A Hague; D J Hicks; C Paraskeva
Journal:  Cancer Res       Date:  1996-05-15       Impact factor: 12.701

3.  DNMT1 and DNMT3b cooperate to silence genes in human cancer cells.

Authors:  Ina Rhee; Kurtis E Bachman; Ben Ho Park; Kam-Wing Jair; Ray-Whay Chiu Yen; Kornel E Schuebel; Hengmi Cui; Andrew P Feinberg; Christoph Lengauer; Kenneth W Kinzler; Stephen B Baylin; Bert Vogelstein
Journal:  Nature       Date:  2002-04-04       Impact factor: 49.962

4.  APC mutations occur early during colorectal tumorigenesis.

Authors:  S M Powell; N Zilz; Y Beazer-Barclay; T M Bryan; S R Hamilton; S N Thibodeau; B Vogelstein; K W Kinzler
Journal:  Nature       Date:  1992-09-17       Impact factor: 49.962

5.  Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene.

Authors:  Y Miyoshi; H Nagase; H Ando; A Horii; S Ichii; S Nakatsuru; T Aoki; Y Miki; T Mori; Y Nakamura
Journal:  Hum Mol Genet       Date:  1992-07       Impact factor: 6.150

Review 6.  Genetic alterations in the adenoma--carcinoma sequence.

Authors:  K R Cho; B Vogelstein
Journal:  Cancer       Date:  1992-09-15       Impact factor: 6.860

7.  Loss of IGF2 imprinting: a potential marker of colorectal cancer risk.

Authors:  Hengmi Cui; Marcia Cruz-Correa; Francis M Giardiello; David F Hutcheon; David R Kafonek; Sheri Brandenburg; Yiqian Wu; Xiaobing He; Neil R Powe; Andrew P Feinberg
Journal:  Science       Date:  2003-03-14       Impact factor: 47.728

8.  Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer.

Authors:  Hiromu Suzuki; D Neil Watkins; Kam-Wing Jair; Kornel E Schuebel; Sanford D Markowitz; Wei Dong Chen; Theresa P Pretlow; Bin Yang; Yoshimitsu Akiyama; Manon Van Engeland; Minoru Toyota; Takashi Tokino; Yuji Hinoda; Kohzoh Imai; James G Herman; Stephen B Baylin
Journal:  Nat Genet       Date:  2004-03-14       Impact factor: 38.330

9.  A variable cytoplasmic domain segment is necessary for γ-protocadherin trafficking and tubulation in the endosome/lysosome pathway.

Authors:  Robert O'Leary; James E Reilly; Hugo H Hanson; Semie Kang; Nicole Lou; Greg R Phillips
Journal:  Mol Biol Cell       Date:  2011-09-14       Impact factor: 4.138

10.  Protocadherin Pcdh2 shows properties similar to, but distinct from, those of classical cadherins.

Authors:  S Obata; H Sago; N Mori; J M Rochelle; M F Seldin; M Davidson; T St John; S Taketani; S T Suzuki
Journal:  J Cell Sci       Date:  1995-12       Impact factor: 5.285

View more
  33 in total

Review 1.  Regulation of Wnt signaling by protocadherins.

Authors:  Kar Men Mah; Joshua A Weiner
Journal:  Semin Cell Dev Biol       Date:  2017-08-01       Impact factor: 7.727

Review 2.  Protocadherins branch out: Multiple roles in dendrite development.

Authors:  Austin B Keeler; Michael J Molumby; Joshua A Weiner
Journal:  Cell Adh Migr       Date:  2015-04-14       Impact factor: 3.405

3.  Contrasting DCIS and invasive breast cancer by subtype suggests basal-like DCIS as distinct lesions.

Authors:  Helga Bergholtz; Tonje G Lien; David M Swanson; Arnoldo Frigessi; Maria Grazia Daidone; Jörg Tost; Fredrik Wärnberg; Therese Sørlie
Journal:  NPJ Breast Cancer       Date:  2020-06-17

4.  Multiple protocadherins are expressed in brain microvascular endothelial cells and might play a role in tight junction protein regulation.

Authors:  Christina Dilling; Norbert Roewer; Carola Y Förster; Malgorzata Burek
Journal:  J Cereb Blood Flow Metab       Date:  2017-01-17       Impact factor: 6.200

Review 5.  Beyond E-cadherin: roles of other cadherin superfamily members in cancer.

Authors:  Frans van Roy
Journal:  Nat Rev Cancer       Date:  2014-01-20       Impact factor: 60.716

Review 6.  Cadherins down-regulation: towards a better understanding of their relevance in colorectal cancer.

Authors:  Lorena Losi; Tommaso Zanocco-Marani; Alexis Grande
Journal:  Histol Histopathol       Date:  2020-06-22       Impact factor: 2.303

7.  Tet proteins influence the balance between neuroectodermal and mesodermal fate choice by inhibiting Wnt signaling.

Authors:  Xiang Li; Xiaojing Yue; William A Pastor; Lizhu Lin; Romain Georges; Lukas Chavez; Sylvia M Evans; Anjana Rao
Journal:  Proc Natl Acad Sci U S A       Date:  2016-12-05       Impact factor: 11.205

Review 8.  Aberrant expression and functions of protocadherins in human malignant tumors.

Authors:  Ming Shan; Yonghui Su; Wenli Kang; Ruixin Gao; Xiaobo Li; Guoqiang Zhang
Journal:  Tumour Biol       Date:  2016-07-24

9.  Epigenetic regulation of DACH1, a novel Wnt signaling component in colorectal cancer.

Authors:  Wenji Yan; Kongming Wu; James G Herman; Malcolm V Brock; François Fuks; Lili Yang; Hongbin Zhu; Yazhuo Li; Yunsheng Yang; Mingzhou Guo
Journal:  Epigenetics       Date:  2013-10-22       Impact factor: 4.528

10.  Long range epigenetic silencing is a trans-species mechanism that results in cancer specific deregulation by overriding the chromatin domains of normal cells.

Authors:  Marta Forn; Mar Muñoz; Daniele V F Tauriello; Anna Merlos-Suárez; Verónica Rodilla; Anna Bigas; Eduard Batlle; Mireia Jordà; Miguel A Peinado
Journal:  Mol Oncol       Date:  2013-08-30       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.